On World Rainforest Day, Jaguar Health Reinforces Commitment to Amazon Rainforest and Sustainable Harvesting Programs for Plant-based Pharmaceuticals
Jaguar chief of sustainability and ethnobotanist Dr.
Over the last 30 years, the Jaguar team and partner organizations have substantially invested in developing the first and only oral plant-based prescription medicine approved under FDA Botanical Guidance while setting a standard for sustainable harvesting
"It was a pleasure to join Beto to discuss the 30-year development history of Mytesi and the Croton lechleri tree's rich history of medicinal use by Indigenous peoples and local communities in
A non-opiate antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy, Mytesi is marketed by Jaguar's wholly owned subsidiary
"Especially on World Rainforest Day, we need to recognize the unique and powerful knowledge traditional peoples have about plants, ecosystems, interrelationships and healing compounds. This knowledge has led to drug products that have changed the world, such as quinine did for malaria," said
During the interview with Forest Trends,
About Forest Trends
Forest Trends works to conserve forests and other ecosystems through the creation and wide adoption of a broad range of environmental finance, markets, and other payment and incentive mechanisms. The nonprofit organization's Communities and Territorial Governance Initiative partners with Indigenous and other forest communities on innovations to secure their rights, livelihoods, and cultures through a strategy built on advocacy, economic self-determination, and cultural integrity.
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the development of possible Mytesi (crofelemer) follow-on indications and development efforts related to lechlemer. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.